First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) - A Network Meta-Analysis by PD-L1

被引：0
|
作者：
San Tan, P. [1 ]
Nazareth Aguiar Junior, P. [2 ]
Husnain, M. [3 ]
Haaland, B. [4 ,5 ]
Lopes, G. [3 ]
机构：
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[2] Fac Med Abc, Clin Oncol, Santo Andre, Brazil
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; Atezolizumab; cost-effectiveness;
D O I：
10.1016/j.jtho.2019.08.970
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-67
引用
收藏
页码：S467 / S467
页数：1
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis
    Peng, Tzu-Rong
    Lin, Hung-Hong
    Tsai, Fang-Pei
    Wu, Ta-Wei
    THORACIC CANCER, 2021, 12 (21) : 2873 - 2885
  • [2] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
    Olivier Bylicki
    Helene Barazzutti
    Nicolas Paleiron
    Jacques Margery
    Jean-Baptiste Assié
    Christos Chouaïd
    BioDrugs, 2019, 33 : 159 - 171
  • [3] PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
    Garcia Campelo, Maria Rosario
    Arriola, Edurne
    Campos Balea, Begona
    Lopez-Brea, Marta
    Fuentes-Pradera, Jose
    de Castro Carpeno, Javier
    Aguado, Carlos
    Perez Parente, Diego
    de Oro Pulido, Fidel
    Ruiz-Gracia, Pedro
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [4] PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
    Majem, Margarita
    Cobo, Manuel
    Isla, Dolores
    Marquez-Medina, Diego
    Rodriguez-Abreu, Delvys
    Casal-Rubio, Joaquin
    Moran-Bueno, Teresa
    Bernabe-Caro, Reyes
    Perez-Parente, Diego
    Ruiz-Gracia, Pedro
    Arroyo, Marta Marina
    Paz-Ares, Luis
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [5] Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer
    Decatris, Marios P.
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2016, 12 (15) : 1805 - 1822
  • [6] Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression >50%
    Freemantle, Nick
    Xu, Yingxin
    Wilson, Florence R.
    Guyot, Patricia
    Chen, Chieh-, I
    Keeping, Sam
    Konidaris, Gerasimos
    Chan, Keith
    Kuznik, Andreas
    Atsou, Kokuvi
    Glowienka, Emily
    Pouliot, Jean-Francois
    Gullo, Giuseppe
    Rietschel, Petra
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [7] Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
    Chen, Wei
    Chen, Jiayi
    Zhang, Lin
    Cheng, Sheng
    Yu, Junxian
    BMC CANCER, 2023, 23 (01)
  • [8] Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
    Wei Chen
    Jiayi Chen
    Lin Zhang
    Sheng Cheng
    Junxian Yu
    BMC Cancer, 23
  • [9] Network Meta-Analysis of First-Line and Maintenance Regimens in EGFR Mutated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    De Lima Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1224 - S1225
  • [10] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    La-Beck, Ninh M.
    Nguyen, Dung T.
    Le, Alex D.
    Alzghari, Saeed K.
    Trinh, Saralinh T.
    PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
12345